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Obesity and diabetes affect more than half a
billion individuals worldwide. Interestingly, the
two conditions do not always coincide and the
molecular determinants of ‘‘healthy’’ versus ‘‘un-
healthy’’ obesity remain ill-defined. Chronic meta-
bolic inflammation (metaflammation) is believed to
be pivotal. Here, we tested a hypothesized anti-
inflammatory role for heme oxygenase-1 (HO-1)
in the development of metabolic disease. Surpris-
ingly, in matched biopsies from ‘‘healthy’’ versus
insulin-resistant obese subjects we find HO-1 to
be among the strongest positive predictors of
metabolic disease in humans. We find that hepa-
tocyte and macrophage conditional HO-1 deletion
in mice evokes resistance to diet-induced insulin
resistance and inflammation, dramatically reducing
secondary disease such as steatosis and liver
toxicity. Intriguingly, cellular assays show that
HO-1 defines prestimulation thresholds for in-
flammatory skewing and NF-kB amplification in
macrophages and for insulin signaling in hepa-
tocytes. These findings identify HO-1 inhibition as
a potential therapeutic strategy for metabolic
disease.INTRODUCTION
The American Medical Association recently voted to recognize
obesity as a disease (http://www.ama-assn.org). Interestingly,
up to one in four individuals currently labeled as obese are actu-
ally metabolically healthy (Stefan et al., 2013), scoring normal on
indices of insulin resistance and systemic inflammation. Impor-
tantly, the factors determining ‘‘healthy’’ versus ‘‘unhealthy’’
obesity remain ill-defined.
Adipose tissuemass, and in particular ratios of ‘‘good’’ subcu-
taneous versus ‘‘bad’’ visceral depots are strongly correlated
with disease; whereas visceral fat expansion is associated with
metabolic disease (Tchkonia et al., 2013), expansion associated
with insulin sensitizers (Virtue and Vidal-Puig, 2008), transplanta-
tion of subcutaneous adipose (Gavrilova et al., 2000), and even
massive subcutaneous expansion (Kusminski et al., 2012) have
all been shown to be disease sparing. Indeed, pronounced
loss of white fat is—with rare exceptions (Pospisilik et al.,
2010)—linked to insulin resistance (Garg, 2011). Using insulin
sensitivity as the hallmark of healthy obesity several controlling
factors have emerged (Johnson and Olefsky, 2013). Visceral
adipocyte hypertrophy and associated hypoxia and fibrosis are
detrimental (Sun et al., 2013). Saturated free fatty acids and
ectopic lipid storage in liver and muscle impair insulin action
(Samuel and Shulman, 2012). Further, reactive oxygen species
(Houstis et al., 2006), mitochondrial function (Szendroedi et al.,
2012), endoplasmic reticulum stress (Hotamisligil, 2010), and
gut microbiota (Burcelin et al., 2012) all provide influence.Cell 158, 25–40, July 3, 2014 ª2014 Elsevier Inc. 25
Importantly, many—if not all—insulin resistance drivers identi-
fied to date converge uniformly upon inflammation and proin-
flammatory signaling (Lumeng and Saltiel, 2011; Odegaard and
Chawla, 2013; Solinas and Karin, 2010). Such chronic inflamma-
tion, so-called ‘‘metaflammation,’’ currently provides a unifying
theory for unhealthy obesity (Gregor and Hotamisligil, 2011).
The concept of metaflammation was born out of the discovery
that tumor necrosis factor-alpha (TNF-a) potently inhibits adi-
pose insulin signaling (Hotamisligil et al., 1993). Subsequent
work implicated additional hallmark activities including inhibitor
of kB kinase (Yuan et al., 2001), c-Jun amino-terminal kinases
(Hirosumi et al., 2002), and protein kinase R (Nakamura et al.,
2010). Two landmark papers described macrophage infiltrates
in adipose as the source of insulin-resistance inducing TNF-a
(Weisberg et al., 2003; Xu et al., 2003). Such infiltrates have since
been characterized as classically activated, proinflammatory
M1-like macrophages (Lumeng et al., 2007; Solinas et al.,
2007), which have proven pivotal to the emergence of metabolic
disease (Patsouris et al., 2008). Importantly, studies now impli-
cate metaflammation as a central feature of human insulin resis-
tance (Capel et al., 2009; Qatanani et al., 2013).
Comparisons of ‘‘cold’’ metaflammation with classical ‘‘hot’’
inflammation reveal few differences (Calay and Hotamisligil,
2013). Here, we tested heme oxygenase-1 (HO-1), a historically
anti-inflammatory molecule that catalyzes heme breakdown to
CO, biliverdin, and free iron (Abraham and Kappas, 2008). In
addition to heme, HO-1 is induced by numerous stressors
including endotoxin, cytokines, and oxidants (Abraham and
Kappas, 2008). In humans, HO-1 loss-of-function leads to early
death (Yachie et al., 1999). Deletion in mice results in high peri-
natal mortality and increased susceptibility to inflammation
(Kapturczak et al., 2004). Interestingly, several studies have
shown that chemical HO-1 induction ameliorates obesity and
diabetes in rodents (Li et al., 2008; Ndisang et al., 2009). How-
ever, these results have failed validation in more specific genetic
models (Huang et al., 2013; Huang et al., 2012), and human
studies show similarly conflicting results (Bao et al., 2010; Shak-
eri-Manesch et al., 2009).
Here, using conditional mouse genetics we show that HO-1
is in fact proinflammatory, potently and independently driving
insulin resistance in the hepatic and macrophage compart-
ments. Against expectations, we find that HO-1 is among the
top predictors of metabolic disease in humans and mice and,
intriguingly, that hepatocyte and macrophage loss-of-function
leads to resistance to diet-induced metaflammation, insulin
resistance, and steatosis. The results indicate that HO-1 is in
fact necessary for the development of metaflammation and
metabolic disease, and call for a re-evaluation of numerous find-
ings in the field. They identify HO-1 as a candidate biomarker for
stratification of metabolically healthy and unhealthy obesity and
provide a framework for selective, personalized therapy.
RESULTS
HO-1 Expression Predicts Insulin Resistance in Mouse
and Man
Over the last years we collected a unique resource of matched
serum, liver, and adipose biopsies from well-characterized indi-26 Cell 158, 25–40, July 3, 2014 ª2014 Elsevier Inc.viduals for studying ‘‘healthy’’ versus ‘‘diseased’’ obesity. Re-
cruited subjects were required to be clinically obese (BMI >
30), to exhibit normal fasting glucose levels, to have no overt
inflammation, and to be free of any medications. Critically,
whereas obese insulin-resistant (obIR) individuals exhibited
clearly elevated insulin resistance (HOMA-IR R 5), obese insu-
lin-sensitive (obIS) individuals were required to show no signs
of systemic insulin resistance, i.e., HOMA-IR% 2. We thus bio-
psied 17 obIS and 27 obIR individuals well-matched for age and
BMI (Table 1) and complemented the samples with biopsies from
6 nonobese individuals. Consistent with their insulin resistance,
the obIR group displayed minimally elevated waist circumfer-
ence, visceral adiposity, triglyceride to HDL ratio, as well as
GLUT4 and HSD11B1 mRNA expression by qPCR (Table 1).
Thus, we assembled a clinical resource to probe early determi-
nants of insulin resistance in obesity.
Interestingly, and in contrast to our initial expectations, we
found elevated HO-1 expression in obIR individuals in both
the liver and visceral fat compartments (Figures 1A and 1B).
HO-1 levels correlated directly with metabolic dysregulation,
increasing progressively from lean to obIS and through to obIR
states (Figures 1A and 1B). Importantly, regression analyses
including seven ‘‘intermediate’’ insulin resistance subjects
(HOMA-IR > 2 and < 5) revealed that liver and adipose HO-1
expression explain 21.7% and 43.3% of HOMA-IR, relationships
maintained in both males and females, and independent of waist
circumference or visceral fat (Tables S1 and S2 available online).
These findings were confirmed on the protein level, and impor-
tantly, placed HO-1 within both the hepatocyte and Kupffer cell
compartments in liver and in macrophages in adipose (Figures
1C and 1D). Of note, HO-1 protein was elevated in both hepatic
compartments in obIR individuals (Figures 1C and 1E). In
adipose, HO-1 was particularly evident in inflammatory
macrophage crown-like structures (Figure 1D). Thus, liver and
adipose HO-1 are potent independent predictors of insulin resis-
tance in man.
Since a proinflammatory role for HO-1 contradicted bulk liter-
ature on the enzyme, we performed an unbiased search for data
sets to validate our findings. We identified five data sets, two in
liver and three in adipose, comparing obese and/or insulin-resis-
tant adult humans with controls, and mined them for any pattern
of HO-1 expression. Impressively, HO-1 was increased in the
metabolically compromised setting in five of five studies. HO-1
was increased in livers of obese versus lean individuals (Fig-
ure 1F) (Pihlajama¨ki et al., 2009) and of diabetic versus nondia-
betic subjects (Figure 1G) (Misu et al., 2010). In adipose, HO-1
was elevated in insulin-resistant obese subjects (Figure 1H)
(NCBI, GEO data set GDS3665). In a rare opportunity to control
for genetic background in the human setting, we mined adipose
expression profiles from monozygotic twins discordant for BMI
and observed HO-1 again to be consistently higher in the obese
sibling (Figure 1I) (Pietila¨inen et al., 2008). Finally, in a landmark
survey of adipose from 387 morbidly obese individuals, HO-1
scored 3rd of all insulin-resistance risk genes (Figure 1J) (Qata-
nani et al., 2013). Thus, liver and adipose tissue HO-1 expression
consistently predict metabolic dysfunction in humans.
To test conservation, we set out to generate a parallel data set
in mice. Similar to humans, mice exhibit substantial HO-1
Table 1. Characteristics of the Study Population
Trait Nonobese obIS obIR pa pb pc
Male/female (n) 3/3 2/15 10/17 0.088 0.089 0.090
Age (years) 40.5 (3.3) 39.2 (2.3) 38.8 (2.3) n.s. n.s. n.s.
BMI (kg/m2) 25.2 (0.9) 40.9 (1.2) 45.0 (0.9) n.d. n.d. n.s.
HOMA-IR 1.0 (0.2) 1.4 (0.1) 7.0 (0.3) n.d. 0.023 n.d.
Waist circumference (cm) 87.8 (2.8) 119.1 (3.4) 132.9 (2.9) n.d. n.d. 0.035
Hip circumference (cm) 101.2 (2.8) 130.5 (2.0) 135.1 (2.2) n.d. n.d. n.s.
Waist/hip ratio 0.87 (0.03) 0.91 (0.02) 0.99 (0.02) <0.001 0.042 0.078
SAT (cm) 2.3 (0.6) 3.1 (0.2) 3.5 (0.2) n.d. n.d. n.s.
VAT (cm) 1.8 (0.4) 5.3 (0.7) 6.9 (0.5) n.d. n.d. 0.025
Insulin (pmol/l) 31.8 (5.9) 44.9 (2.2) 201.1 (10.6) n.d. 0.027 n.d.
Glucose (mmol/l) 4.8 (0.2) 4.8 (0.1) 5.5 (0.1) n.d. n.s. n.d.
Cholesterol (mmol/l) 5.6 (0.4) 4.8 (0.2) 4.9 (0.2) n.s. n.s. n.s.
Triglycerides (mmol/l) 1.3 (0.4) 1.2 (0.1) 2.2 (0.3) 0.002 n.s. 0.006
HDL cholesterol (mmol/l) 1.8 (0.2) 1.5 (0.1) 1.2 (0.1) <0.001 n.s. 0.007
LDL cholesterol (mmol/l) 3.2 (0.2) 2.8 (0.2) 2.8 (0.2) n.s. n.s. n.s.
Triglyceride/HDL ratio 1.6 (0.4) 2.1 (0.3) 4.7 (0.7) <0.001 n.s. 0.001
C-reactive protein (mg/l) 4.5 (3.1) 5.6 (1.1) 7.2 (0.1) n.s. n.s. n.s.
GLUT4 mRNA (AU) 1.36 (0.27) 1.00 (0.10) 0.53 (0.05) <0.001 n.s. 0.001
HSD11B1 mRNA (AU) 0.63 (0.18) 1.00 (0.15) 2.28 (0.35) <0.001 n.s. <0.001
Data are numbers of observations or unadjusted and untransformed means (SEM). Two-sided p values obtained from Chi-square test or ANOVA
(Scheffe´-Test for subgroup comparisons adjusted for age and sex) for categorical or continuous data, respectively.
acomparison among all groups.
bnonobese controls versus obese insulin-sensitive (obIS).
cobIS versus obese insulin-resistant (obIR); participants (total) n = 50 (6/17/27; nonobese/obIS/obIR; n = 48 (6/16/26) for SAT and VAT; obIS, HOMA-IR
% 2.0; obIR, HOMA-IR > = 5.0; n.s., not significant; n.d., not determined; SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue; AU, arbitrary
unit. See also Tables S1 and S2.expression in the lung, kidney, and spleen and, interestingly, in
metabolic organs including the liver and white adipose tissue
(Figure S1A). To explore mouse HO-1 variation with metabolic
disease, we generated a large cohort of high-fat-diet (HFD)-
treated male C57BL/6J mice, stratified them according to
glucose (Figure S1B) and insulin tolerance (Figure S1C) and
selected subgroups exhibiting either insulin sensitivity (IS) or in-
sulin resistance (IR) despite comparable weight gain on the HFD
regimen (Figure S1D). Of note, and in complete agreement with
our human findings, HO-1 expression in liver (Figure 1K) and
adipose (Figure 1L) was directly proportional to severity of meta-
bolic dysregulation. Again, measures were confirmed on the pro-
tein level, in both liver (Figure 1M) and epididymal adipose tissue
(Figure 1N). Importantly, the obese-IR and -IS groups did not
differ in body weight (Figure S1D), and were matched for age
and developmental environment. Thus, hepatic and adipose tis-
sue HO-1 predict insulin resistance in mouse and man.
Hepatocyte HO-1 Knockout Mice Are Insulin
Hypersensitive
To directly assess the role of HO-1 in the etiology of metabolic
disease, we generated mice bearing a conditional allele for
HO-1 (HO-1fl/fl) (Figures S2A and S2B). First, we crossed them
to Albumin-Cre transgenic mice (Alb-Cre) to obtain liver (hepato-
cyte)-specific HO-1 knockouts (Lhoko). Efficient deletion was
confirmed on the DNA, protein and activity levels (Figures2A, 2B, and S2C). Functional deletion of HO-1 was confirmed
in vivo by examining HO-1 expression in whole livers upon hemin
injection, a heme analog known to induce HO-1 expression and
activity (Figure 2C). Thus, we generated hepatocyte-specific
HO-1 mutant mice.
Lhoko mice were born at Mendelian ratios, developed
normally, and exhibited normal liver morphology as well as
serum parameters (Figures S2D and S2E). Importantly, Lhoko
animals exhibited completely normal glucose and insulin toler-
ance relative to their littermate controls (Figures S2F and S2G),
showing no evidence of HO-1 imposed anti-inflammatory tone
in the naive state. Remembering that our observations of
disease predicting HO-1 were made in metabolically stressed
individuals, we challenged Lhoko mice with HFD. With respect
to adiposity, Lhoko mice showed no difference in HFD-induced
body weight gain relative to littermates (Figure S2H). Similarly,
they maintained unremarkable oral glucose tolerance (Fig-
ure 2D). Intriguingly though, insulin tolerance, fasting insulin,
and HOMA-IR all indicated significantly increased insulin sensi-
tivity in the HFD-treated Lhoko animals (Figures 2D and 2E), a
clear indication of improved metabolic health. In agreement
with these findings, serum measures of hepatotoxicity including
alanine transaminase (ALAT), aspartate transaminase (ASAT),
and ASAT/ALAT ratios were clearly improved (Figures 2F). To
understand the insulin sensitivity on a cellular level, an insulin
bolus was administered directly into the portal vein ofCell 158, 25–40, July 3, 2014 ª2014 Elsevier Inc. 27
Figure 1. HO-1 Levels Predict Insulin Resistance in Mouse and Man
(A andB) qPCR analysis ofHO-1mRNA in (A) liver and (B) visceral adipose biopsies obtained from obese insulin-sensitive (obIS) and obese insulin-resistant (obIR)
humans.
(C and D) Immunohistochemical staining for HO-1 in (C) liver and (D) obIR visceral fat biopsies. Scale bar, 50 mm.
(E) Percentage of HO-1 positive hepatocytes in obIS and obIR liver biopsies.
(F–I) HO-1 mRNA levels obtained from public microarray data sets; (F and G) liver (H and I) adipose tissue. Numbers in bars represent study participants.
(legend continued on next page)
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HFD-treated Lhoko and control animals, and liver biopsies
taken over 10 min. Intriguingly, loss of HO-1 induced stark
augmentation and acceleration of key upstream insulin
signaling activation events including insulin receptor (INSR)
and AKT phosphorylation (Figure 2G). The effects were highly
reproducible, and evident within 2 min of injection. Indicating
more widespread positive effects of hepatic HO-1 deletion,
examinations of muscle and adipose responses in the same
animals revealed moderately elevated pAKT (Figure 2G). In
keeping with these improvements in metabolic function, oil
red O staining and biochemical measures revealed attenuated
liver steatosis in HFD-treated Lhoko animals (Figures 2H and
2I). Gluconeogenic and lipogenic programs were largely unal-
tered (Figure S2I). Together, these findings comprise direct ge-
netic evidence that loss of hepatocyte HO-1 in vivo induces
proximal insulin signaling hypersensitivity and resistance to
HFD-induced metabolic sequelae.
To corroborate these data, we also performed the opposite
genetic experiment, acutely overexpressing HO-1 via tail vein
injection of adenoviral HO-1 (Figures S2J and S2K). Critically,
and in direct support of the human and Lhoko data, 1 week of
5-fold HO-1 overexpression in unchallenged chow-fed
C57BL/6Jmice triggered glucose intolerance, insulin resistance,
and elevated HOMA-IR relative to Adeno-LacZ injected controls
(Figures 2J, 2K, and S2L). Thus, genetic gain- and loss-of-func-
tion studies in vivo indicate that hepatocyte HO-1 exacerbates
insulin resistance, steatosis, liver damage and metabolic
disease.
Macrophage HO-1 Knockout Mice Resist Metabolic
Disease
Considering the observed increases in macrophage HO-1 in in-
sulin-resistant liver and adipose in both mouse and man, and
the central role of macrophages in metaflammation, we next
tested the contribution of macrophage HO-1 toward insulin
resistance. We crossed our conditional HO-1 mice to macro-
phage deleting LysM-Cre transgenic animals, creating macro-
phage HO-1 knockout (Macho) mice. Equal and efficient deletion
was confirmed in naive, as well as lipopolysaccharide (LPS)/
interferon (IFN)g-driven proinflammatory (M1) and interleukin
(IL)-4/IL-13-driven anti-inflammatory (M2) bone-marrow-derived
macrophages (BMDMs; Figures 3A–3C). Similar to Lhoko ani-
mals, Macho mice were born at Mendelian ratios, developed
normally, exhibited normal white blood cell counts, and ap-
peared robust and healthy (Figures S3A and S3B and data not
shown). Importantly, metabolic profiling was equally unremark-
able in the unchallenged state with no detectable alterations in
body weight, food intake, glucose tolerance, insulin sensitivity,
or plasma-free fatty acid levels (Figures S3A–S3F). Thus, macro-
phageHO-1 is dispensable for normal growth, development, and
metabolic homeostasis.(J) Rank order of 968 visceral adipose tissue genes correlating with HOMA-IR and
genes) obesity. p values for Spearman correlation coefficients (HOMA-IR versus
significance cut-off at p < 0.01, corrected for multiple testing.
(K and L) qPCR analysis of HO-1 expression in (K) liver, and (L) epididymal adipos
(M and N) Immunoblot analysis for HO-1 in (M) liver, and (N) epididymal adipose
Results are mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S1As mentioned above, bulk literature would have predicted, if
anything, enhanced inflammation upon HO-1 deletion. In an
attempt to unmask such a phenotype, we again turned to HFD.
Intriguingly, and again in contrast to expectations, we observed
marked increases in glucose clearance and insulin sensitivity in
Macho animals after a 16 week HFD regimen (Figures 3D and
3E). Indeed, even body weight gain was slightly reduced
(Figure 3D)—despite no measurable change in food intake (Fig-
ure S3G). Importantly, all aspects of improved glucose homeo-
stasis were evident before body weight differences emerged
(data not shown) and, independently, when comparing body-
weight-matched animals at the experiment’s end (Figure 3F).
Interestingly, the metabolic improvements elicited by macro-
phage HO-1 loss were systemic. Both liver morphology and his-
tology revealed clear reductions in hepatic steatosis in Macho
animals (Figure 3G), improvements confirmed by reduced mea-
sures of lipid content and liver toxicity, as well as lipogenic and
gluconeogenic profiles (Figures 3H, 3I, and S3H). Specifically,
expression of the lipogenic factors Pparg, Srebf1, Cd36, and
Fasn were reduced in HFD-Macho livers as well as G6pc, which
mediates hepatic glucose output (Figure 3H). Expression of in-
flammatory Tnf, Il6, and Il1b were equally reduced (Figure 3H),
a contrast to elevated anti-inflammatory Il10 (Figure 3H). Impor-
tantly, HO-1 expression, whichwe show here to be proinflamma-
tory, was not only reduced in the myeloid compartment, but
importantly also in hepatocytes of the Macho mice (Figure 3G),
indicating that macrophage HO-1 is necessary for effective
transmission of inflammatory status to target tissues. Consistent
with our previous findings, liver, muscle, and fat responses to in-
traportal insulin were significantly enhanced in the HFD-treated
Macho mice (Figure S3I). These findings are in direct agreement
with our observations that HO-1 expression in both hepatocytes
and macrophages of human obese liver predicts disease
severity. An aside on the observed body weight difference,
Macho animals exhibited a minor increase in energy expenditure
(Figure 3J) independent of any altered activity (Figure 3K) or res-
piratory quotient (Figure S3J). These data are consistent with the
observed system-wide improvements in metabolic homeosta-
sis. In all, the data of both mouse models and the human cohort
implicate myeloid HO-1 as an effector of metabolic disease.
Thus, macrophage HO-1 is necessary for the manifestation of
HFD-induced metaflammation.
Reduced Metaflammation and Improved Adipose Tissue
Architecture in Macho Mice
Steatosis results in part from fatty acid spill-over resulting from
inflammation, insulin resistance, and improper lipolysis. In line
with the reduced steatosis, HFD-Macho mice exhibited reduced
fasted and fed serum-free fatty acids (Figure 4A). Further, exam-
ination of HFD-Macho epididymal fat revealed dramatic
improvements in metaflammation. Included were near-absencepredicting metabolically healthy (251 protective genes) and unhealthy (717 risk
expression values) obtained from public data set. Dotted line represents the
e obtained from obese IS and obese IR C57BL/6J mice after 16 weeks on HFD.
obtained from obese IR and obese IS C57BL/6J mice after 16 weeks of HFD.
and Tables S1 and S2.
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of crown-like structures (Figure 4B), reduced adipocyte size
(Figures 4B and 4C), and a substantial reduction in macrophage
infiltration (Figure 4D). Importantly, these healthy metabolic attri-
butes were manifest in the face of clear obesity. Consistent with
this ‘‘healthy’’ obesity profile, HFD-Macho animals exhibited
clear reductions in the systemic indicators of metaflammation,
namely TNF-a, IL-1b, MCP-1, and RANTES (Figure 4E). Adipo-
nectin (Adipoq) and retinol binding protein-4 (Rbp4) mRNA levels
were increased in HFD-Macho mouse adipose, whereas leptin
(Lep) levels were not affected (Figure 4F). Notably, the Rbp4
mRNA changes were not manifest on the protein level (Fig-
ure 4G). Thus, Macho mice exhibit reduced systemic and adi-
pose tissue metaflammation.
The human andmouse data to this point suggested a predom-
inantly myeloid and hepatic role for HO-1 in metaflammation and
insulin resistance. We also largely ruled out the contribution of
HO-1 in muscle, adipocyte, and pancreatic b-cell compart-
ments, as targeted deletion in these depots did not affect
HFD-challenged body weight accumulation, glucose, or insulin
tolerance (Figures S4A–S4C).
Next, we asked how HO-1 elicits metaflammation. We purified
and FACS analyzed the nonadipocyte stromal vascular fraction
(SVF) from epididymal adipose of HFD-treated Macho and con-
trol mice. In line with the reduced evidence for metaflammation,
HFD-Macho adipose tissue contained a 2-fold reduction in
proinflammatory CD11c+ and CCR2+ macrophage infiltrates,
while protective M2-like MGL+ macrophage numbers were
increased (Figures 4H–4J and Figure S4D). These observations
were equally reflected in qPCR measures of Cd68, Itgax/
Cd11c and the chemokine receptors Ccr2 and Ccr5 in whole-
adipose RNA preparations (Figures S4E and S4F), as well as
confocal evidence of improved adipose tissue architecture
(Figure 4K). In support of a conserved system in humans, re-
examination of our human adipose biopsies revealed an increase
in total macrophage number and M1-like marker expression
(Table S3). Importantly, HO-1 exhibited a tight positive correla-
tion with M1-like marker expression (TNF, ITGAX/CD11c),
whereas M2-like markers showed no correlation (MRC1/
CD206) or an inverse relationship (CLEC10A/CD301, CCL18)
(Table S4). Importantly, these findingswere independent of waist
circumference and again maintained after correcting for visceral
fat. Thus, macrophage HO-1 is necessary to induce proinflam-
matory macrophage skewing and disruption of adipose tissue
architecture.Figure 2. Hepatocyte HO-1 Knockout Mice are Insulin Hypersensitive
(A) HO-1 immunoblot of liver obtained from control and Lhoko mice.
(B) HO activity in liver homogenates, nR 6 per group.
(C) Immunohistochemical staining for HO-1 in livers of vehicle and hemin injecte
(D) Oral glucose and insulin tolerance tests on HFD.
(E) HOMA-IR of control and Lhoko mice after 16 weeks on HFD.
(F) Serum levels of liver enzymes after 16 weeks on 60% HFD, nR 4 per group.
(G) In vivo activation of liver insulin signaling. HFD-fed mice were injected with in
blotting. A representative result from three independent experiments is shown.
(H) Liver triglyceride content, n = 3 per group.
(I) H&E, oil red O and HO-1 staining of representative liver sections obtained from
(J) Insulin tolerance tests in AdLacZ and AdHO-1 injected C57BL/6J animals, n =
(K) HOMA-IR of AdLacZ and AdHO-1 injected C57BL/6J animals, n = 7 per grou
Results are mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S2.HO-1 Loss Induces an Anti-Inflammatory Metabolic
Signature and Blunts NF-kB Signaling
Next, to gain insight into the attenuated metaflammatory pheno-
type, we harvested and in vitro differentiated bone marrow
progenitors from unchallenged, chow-fed Macho animals and
controls intomacrophages (BMDMs). Using TNF-a, we activated
BMDMs and examined NF-kB signaling. Using phospho-IkBa as
a surrogate for activation, we found a clearly diminished NF-kB
response in Macho BMDMs upon induction (Figure 5A). Impor-
tantly, this finding was confirmed using more direct assays as
well: RelA/p65 nuclear translocation was reduced (Figure 5B),
its target-sequence binding by EMSA was reduced (Figure 5C),
and NF-kB target gene expression including Nfkbia/IkBa, Tnf,
and Nos2/iNos was reduced (Figure 5D). Further, chromatin
immunoprecipitation measures of endogenous NF-kB promoter
binding at known target genes Nos2 and Tnf also showed clear
reductions (Figure 5E). Thus HO-1-deficient BMDMs have
blunted NF-kB signaling.
We and others have previously shown that oxidative meta-
bolism is a signature of activated M2-like macrophages, that
activatedM1-like proinflammatory cells display amore glycolytic
metabolic profile, and that direct alterations in metabolism can
regulate NF-kB signaling potential (Haschemi et al., 2012; Rodrı´-
guez-Prados et al., 2010; Vats et al., 2006). Intriguingly, when
assessing these parameters in naive BMDMs, we found clearly
elevated basal and spare respiratory capacity, as well as ATP-
turnover in the HO-1-deficient cells (Figures 5F and 5G). Finding
all three hallmarks of an M2 ‘‘aerobic signature’’ already in non-
stimulated Macho BMDMs indicated that HO-1 is required for
proper metabolic programming in the most basal cellular state,
and that such ‘‘pre-’’programming may potently influence
macrophage skewing and thus whole-body inflammation.
Indeed, we observed consistent reductions in TNF-a, IL-1b,
and IL-6 secretion in Macho BMDMs relative to controls (Fig-
ure 5H). Thus, HO-1 is required for metabolic programming of
naive macrophages, and thus, for proper TNF-a- and LPS-
induced skewing and activation.
HO-1 Suppresses OxPhos and ROS Signaling
We next asked whether mitochondrial changes might constitute
a common molecular link between the liver and myeloid pheno-
types (Cheng et al., 2009). Indeed, when repeating our measures
on both systems, parallels were evident for essentially all
measures. Like Macho BMDMs, primary Lhoko hepatocytesd control and Lhoko mice. Scale bar, 100 mm.
sulin, tissue biopsies taken at the indicated times, and analyzed by immuno-
HFD-fed control and Lhoko mice. Scale bar, 200 mm.
7 per group, p value 1 sided.
p.
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exhibited increased basal, spare as well as maximal respiratory
capacity (Figures 6A and S5A). Notably, these effects were inde-
pendent of any obvious underlying changes in coupling effi-
ciency (Figure S5B), mitochondrial DNA content (Figure S5C),
mitochondrial mass (Figure S5D), and respiratory chain stoichi-
ometry (Figure S5E). Interestingly, qPCR analysis revealed clear
andwidespread upregulation of the entire mitochondrial reactive
oxygen species (ROS) detoxification system, from glutathione
processing to the mitochondrial-specific superoxide dismutase
2 (Sod2), again in both systems (Figure 6B), indicating that the
increased mitochondrial flux was coupled to the induction of
ROS quenching machinery. Notably, these changes were
confirmed directly, with the findings of increased SOD activity
(Figure 6C) and indirectly, with an 50% increase in intracellular
H2O2, the product of SOD, and an increase of cytosolic ROS,
again in both knockout cell types (Figures 6D and S5F). Recent
studies have suggested that mild ROS elevations activate mito-
chondrial respiration (Mailloux et al., 2013). If ROS balance was
altering oxidative capacity (Figure 6A) then mitochondrial func-
tion in the knockout cells should be particularly sensitive to anti-
oxidants. In line with this idea, 1 hr preadministration of the
potent ROS quencher N-acetyl-cysteine (NAC) reverted HO-1-
deficient mitochondrial functional parameters to control levels
(Figure 6E). Thus, HO-1 regulates acute ROS thresholding of
mitochondrial respiration.
ROS have previously been linked to INSR activation via impair-
ment of protein tyrosine phosphatase nonreceptor type 1
(PTPN1/PTP1B) (Tiganis, 2011) and to nuclear factor-erythroid-
derived 2-like (NFE2L2/NRF2) function via impairment of the
inhibitory protein kelch-like ECH-associated protein 1 (KEAP1)
(Kobayashi et al., 2006). Because activation of INSR and NRF2
alone would explain the majority of phenotypes observed, we
tested their activation state in our most naive HO-1 knockout
models. Importantly, we found increased nuclear translocation
(Figure 6F) and target-binding activity (Figure 6G) of NRF2 in
Macho BMDMs and decreased PTP1B activity (Figure 6H) and
acute INSR activation (Figure 6I) in naive, chow-fed Lhoko livers.
Notably, in vitro reconstitution of HO-1 expression completely
reverted mitochondrial respiratory changes (Figure S5H), down-
stream pINSR increases (Figure S5G), and TNF-a and IL-1b
blunting (Figure S5I) on a timescale paralleling the 1–2 days ex-
pected for adenoviral HO-1 re-expression. This data set sup-
ports a mechanism where HO-1 continuously limits activation
of key signaling systems through an acute and ROS-dependentFigure 3. Macrophage HO-1 Knockout Mice Resist Metabolic Disease
(A) qPCR analysis of HO-1mRNA levels in BMDMs generated from control and M
for 24 hr.
(B) Immunoblot for HO-1 in naive BMDMs derived from indicated genotypes.
(C) HO activity in naive BMDMs generated from LFD-fed control and Macho mic
(D) Body weight gain of control and Macho mice on 60% HFD.
(E) Oral glucose and insulin tolerance tests, corresponding blood glucose and in
(F) Oral glucose and insulin tolerance tests, corresponding blood glucose and in
(G) Liver aspects and stainings of representative liver sections obtained fromHFD
Scale bar, 50 mm.
(H) Relative mRNA levels of inflammatory, lipogenic, and gluconeogenic genes in
(I) Liver triglyceride and cholesterol content, nR 5 per group.
(J and K) Energy expenditure and activity of body-weight-matched control and M
Results are mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S3.mechanism. Again all key phenotypes were observed in naive
unchallenged cells, lending further support to the notion that
HO-1 contributes to the ‘‘pre’’-programming of cellular function.
DISCUSSION
Here, we show that HO-1 drives insulin resistance in mouse and
man. In the absence of macrophage HO-1 animals fail to develop
metaflammation and key hallmarks of metabolic disease. The
findings redefine the current view of HO-1, have substantial
implications for the stratification of healthy and unhealthy
obesity, and open the door for HO-1 inhibitors as a new thera-
peutic strategy for obesity and diabetes.
Intersecting strongpatient datawith genetic evidence fromfive
tissue-specific HO-1 deletion models, as well as overexpression
and genetic rescue scenarios, we find a clear proinflammatory
role for HO-1 in metabolic control and thus break dogma.
Induction of HO-1 by systemic cobalt-protoporphyrin (CoPP)
administration has previously been reported to ameliorate
obesity and diabetes in mice (Li et al., 2008). Indeed, much of
our knowledge of HO-1 biology has relied on CoPP. That said,
key studies raise concerns about CoPP specificity as an ‘‘HO-1
agonist.’’ Specifically, CoPP acts indirectly, by decreasing
BACH1 and increasing NRF2 protein levels (Shan et al., 2006).
CoPP inhibits ALAS1 function (Zheng et al., 2008), and recent
data also suggest effects on FOXO1 (Liu et al., 2013). Together,
NRF2, ALAS1 and FOXO1 impact tens if not hundreds of down-
stream targets including heme synthesis, mitochondrial respira-
tion, cytochrome function, and much more. Also, CoPP blocks
HO-1’s interaction with the key proinflammatory mediator IFN
regulatory factor 3 (IRF3) (Koliaraki and Kollias, 2011).
In the liver, we found that HO-1 deficiency promotes insulin
sensitivity and reduces diet-induced fatty liver disease. This
overall finding is in line with a study showing that in the context
of IRS1/IRS2 double-knockout, HO-1 links insulin signaling dys-
regulation to impaired mitochondrial function (Cheng et al.,
2009). Critically, we observed a brake-like, negative regulator
effect on insulin activation even in healthy, chow-fed animals.
Also in macrophages, HO-1 loss blunted NF-kB signaling poten-
tial in the unstimulated state, even in naive, not-yet polarized
cells. These findings indicate a novel role for HO-1 in the meta-
bolic regulation of cellular signaling thresholds. It will be inter-
esting to see whether additional signaling pathways exhibit
similar threshold control via HO-1.acho mice, naive and polarized with LPS/IFNg (M1-like) or IL-4/IL-13 (M2-like)
e, n = 3 per group.
sulin levels, n = 10–15 per genotype.
sulin levels in body-weight-matched animals, n = 7 per genotype.
-fed control andMachomice for H&E, oil red O, HO-1 (red), andMAC-2 (brown).
liver samples, n = 4 per group.
acho mice, n = 7 per genotype.
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Mechanistically, the signal thresholding effects of HO-1
appear to have common ground. HO-1 loss increases mitochon-
drial respiration, antioxidant capacity, and consequently, H2O2
production. Our findings are consistent with detailed examina-
tions of redox regulation of NRF2 and PTP1B in the literature
and their downstream effects on INSR and NF-kB responses
(Kobayashi et al., 2006; Thimmulappa et al., 2006; Tiganis,
2011). Here, we add HO-1 as a new upstream effector of such
redox-dependent signal ‘‘preconditioning.’’
Corroborating these notions, macrophage HO-1 knockout
mice have been independently reported elsewhere to exhibit
an anti-inflammatory phenotype (Tzima et al., 2009). Using
polyI:C and LPS as stimuli, the authors found that HO-1 was
necessary for full activation of thioglycollate elicited peritoneal
macrophages. Our study and theirs, together, provide definitive
genetic evidence that HO-1 is necessary for both ‘‘cold’’ and
‘‘hot’’ inflammation. Intriguingly, Tzima et al. reported no change
of NF-kB activation, a contrast perhaps attributable to differ-
ences in M1-like activation between the BMDMs used here,
and thioglycollate elicited peritoneal macrophages (Ghosn
et al., 2010). Our data are also in line with improvements in
glucose handling observed in HFD-fed recipient mice trans-
planted with HO-1 haploinsufficient bone marrow (Huang et al.,
2012). Notably, our observation of an M2-like aerobic signature
in unstimulated Macho BMDMs indicates that HO-1 regulates
cell fate skewing even prior to stimulation, and therefore that
HO-1 may fine tune pro- versus anti-inflammatory cell ratios. It
will be interesting to see if HO-1 and associatedmetabolic skew-
ing in precursor cell populations will predict outcome in classical
inflammatory disorders.
Along similar lines, our data suggest a trigger-like role for HO-1
in metaflammation and insulin resistance and thus indicate high
prognostic value for detecting disease onset. The observations
are certainly generalizable, corroborated by multiple indepen-
dent patient cohorts including human diabetes (Misu et al.,
2010), generalized obesity (Qatanani et al., 2013), and obese
monozygotic twins (Pietila¨inen et al., 2008). These data and our
own, show that liver and adipose HO-1 predict disease severity
independently of age, sex, and degree of adiposity, and that they
correlate specifically with pro- but not anti-inflammatory
markers. Careful examination reveals that even our obIS group
showed earliest signs of insulin resistance relative to nonobeseFigure 4. Macrophage HO-1 Knockout Mice Resist Metaflammation
(A) Serum-free fatty acid levels measured in fed and fasted states on HFD, nR
(B) H&E staining of epididymal adipose of HFD fed control and Macho mice. Sca
(C) Adipocyte size distribution in epididymal fat of HFD fed control and Macho mi
n = 6 per group. n = number of adipocytes.
(D) Immunofluorescence staining for MAC-2 and confocal imaging of whole-m
experiments is shown. Scale bar, 200 mm.
(E) Serum levels of proinflammatory cytokines, nR 3 per group.
(F) qPCR analysis of adipokines in epididymal fat isolated from control and Mach
(G) Serum adipokine levels in control and Macho mice, n = 4 per group.
(H–J) Flow cytometric analysis of the SVF isolated from epididymal white adipose t
cells and examined for CD11b coexpression to obtain total macrophage numbe
subpopulations is presented; (J) distribution of CD11c+ MGL and CD11c MGL
(K) Immunofluorescence staining for perilipin (red) andMAC-2 (green) of whole-mo
is shown. Scale bar, 100 mm.
Results are mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S4,controls with elevations in HOMA-IR, insulin and nonsignifcant
increases in GLUT4 and HSD11B1 mRNA (Table 1). HO-1 had
significant predictive power in distinguishing these groups.
Thus, it will be most interesting to evaluate the predictive power
of blood HO-1 levels in detecting pre- and early disease states.
Ending actually with a theorectical and technical unknown, our
study leaves unanswered the potential role of Kupffer cells, and
Kupffer cell HO-1, in the etiology of steatosis, particularly in the
Macho animals. While reported to delete strictly in the circulating
macrophage compartment of the liver (Maeda et al., 2005), we
findwhat appears to be LysM-Cremediated deletion in the entire
liver myeloid compartment, including Kupffer cells, specifically
after long-term HFD. Increased promiscuity of Cre-drivers
upon HFD would certainly not be a new concept. The findings
indicate that the stark improvements observed in HFD-Macho
livers could well be supported by HO-1 deletion in Kupffer cells.
EXPERIMENTAL PROCEDURES
Human Study Population
Study subjects included 51 obese patients and 6 nonobese controls that
underwent weight-reducing surgery or elective surgical procedures such as
cholecystectomy. Participants were included if they had fasting plasma
glucose levels <7.0 mmol/l, no history of diabetes, no medications, no weight
changes >3% during the previous 2 months, C-reactive protein (CRP) levels
<20 mg/l, and normal blood leukocyte counts. For further information, see
the Extended Experimental Procedures.
Metabolically Healthy and Unhealthy Obese Mice
Age- and body-weight-matched C57BL/6J mice were selected based on their
response in glucose and insulin tolerance tests after 16 weeks on HFD.
Glucose and Insulin Tolerance Tests
Glucose and insulin tolerance tests were performed as described in the
Extended Experimental Procedures.
Generation of Tissue-Specific HO-1 Knockout Mice
All mouse models are described in the Extended Experimental Procedures.
Animals were kept on a 12 hr light/dark cycle with free access to food and
water and housed in accordance with international guidelines. Dietary inter-
ventions started at 6 weeks of age using diets which contained 10% and
60% calories of fat (Research Diets, D12450B and D12492).
Heme Oxygenase Activity
HO activity was determined as outlined in the Extended Experimental
Procedures.7 per group.
le bar, 200 mm.
ce as determined by quantitative morphometry of H&E stained tissue sections,
ount epididymal fat pads. A representative result from three independent
o mice, n = 4 per group.
issue (WAT) of HFD fed control andMachomice; (H) Cells were gated for F4/80+
rs; (I) The number of CD11c+, CCR2+ and MGL+ adipose tissue macrophage
+ adipose macrophages, n = 3 mice per group.
unt epididymal fat. A representative result from three independent experiments
Tables S4 and S5.
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In Vivo Liver Insulin Signaling
For examination of in vivo insulin signaling, mice were fasted for 2 hr, anesthe-
tized and injected with insulin. Liver, muscle and adipose were removed at the
indicated times.
Indirect Calorimetry
Indirect calorimetry and activity measurements were performed as reported
elsewhere (Pospisilik et al., 2010) and as described in the Extended Experi-
mental Procedures.
Flow Cytometry
SVF cells were obtained by collagenase digestion from epididymal adipose
tissue as described (Todoric et al., 2011). FACS analysis was performed as
described (Lumeng et al., 2007) and outlined in the Extended Experimental
Procedures.
Nuclear Translocation Assay
Naive BMDMswere stimulated with 10 ng/ml TNF-a or medium only for 30 and
60 min, fixed in ice-cold methanol, washed, and stained with anti-RelA/p65
antibody (Santa Cruz Biotechnology). Nuclei were counterstained with DAPI.
Electrophoretic Mobility Shift Assay
Nuclear extracts were prepared from BMDMs as described in the Extended
Experimental Procedures. EMSA was performed using the NF-kB EMSA
kit (LI-COR Biosciences) according to the manufacturer’s instructions. For
supershift assays anti-RelA/p65 (Santa Cruz Biotechnology), anti-p50
(Millipore), and anti-rabbit IgG (Vector Laboratories) was used. Unlabeled
double-stranded NF-kB probe was used to test specific binding. Samples
were separated on a nondenaturing polyacrylamide gel. NF-kB DNA binding
was visualized using the LI-COR Odyssey Imaging System.
Chromatin Immunoprecipitation Assay
ChIP assayswere performed using theMAGnify ChIP Kit (Life Technologies) as
detailed by the manufacturer’s instruction and as described in the Extended
Experimental Procedures.
Oxygen Consumption Assay and Bioenergetic Profile
OCR was measured using the XF24 Flux Analyzer (Seahorse Bioscience) as
described (Teperino et al., 2012). For details see Extended Experimental
Procedures.
PTP1B Activity Assay
PTP1B activity was determined as outlined in the Extended Experimental
Procedures.
Hydrogen Peroxide Measurements
Hydrogen peroxide (H2O2) production was measured using the Amplex Red
Hydrogen Peroxide/Peroxidase Assay Kit (Invitrogen).Figure 5. Attenuated NF-kB Signaling and Anti-Inflammatory Metaboli
(A) pIkBa and IkBaweremeasured by immunoblotting in BMDMs from control and
the indicated times. b-Actin was used as internal loading control.
(B) RelA/p65 nuclear translocation assay. Naive BMDMs were stimulated with TN
immunofluorescent staining. Nuclei were stained with DAPI, and the percentage o
Scale bar, 50 mm.
(C) EMSA. Nuclear extracts were prepared from control and Macho BMDMs stimu
binding was verified by adding a 100-fold excess of unlabeled double-stranded
assays using anti-RelA/p65 and anti-p50 antibodies.
(D) RelativemRNA expression of NF-kB target genes in BMDMs generated from LF
for 60 min, n = 3 per group.
(E) qPCR analysis of NF-kB targets Tnf andNos2 in chromatin immunoprecipitatio
(F and G) Oxygen consumption rates (OCR) and mitochondrial function of naive
(H) Cytokine secretion of LPS stimulated control and Macho BMDMs, n = 3 per
Results are mean ± SEM n = 2–3 independent experiments. *p < 0.05, **p < 0.01Superoxide Dismutase Assay
Superoxide dismutase (SOD) activity was measured using a commercially
available test kit (Cayman) according to manufacturer’s instructions.Adenovirus Experiments
BMDM rescue experiments were performed using RGD-fiber-modified adeno-
virus particles (Vector Biolabs). In vivo grade viruses were produced to target
livers and isolated primary Lhoko hepatocytes. For details, refer to the
Extended Experimental Procedures.NRF2 DNA-Binding Activity
The NRF2 TransAM ELISA-kit (Active Motif) was used to evaluate NRF2 DNA-
binding activity according to the manufacturer’s protocol.Statistical Analysis
Data are expressed as mean ± standard error of the mean (SEM) unless other-
wise specified. Statistical analyses were performed as described in the
Extended Experimental Procedures. All reported p values are two-tailed
unless stated otherwise. p < 0.05 was considered to indicate statistical
significance.Other Methods
See Extended Experimental Procedures.SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, six
tables, and five figures and can be found with this article online at http://dx.
doi.org/10.1016/j.cell.2014.04.043.AUTHOR CONTRIBUTIONS
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